Earnings Risk

Showing 2835 articles
Business

Idorsia's Latin American Gambit: QUVIVIQ Deal with EMS Signals Strategic Shift Amid Pipeline Scrutiny

Idorsia's exclusive licensing agreement with EMS to commercialize insomnia drug QUVIVIQ across Latin America marks a key step in its global expansion. The deal, involving $20 million in milestones and royalties, arrives as long-term data for its Fabry disease candidate lucerastat puts the spotlight on the company's broader late-stage pipeline and persistent financial pressures.

Business

UPS Unveils Sweeping Network Overhaul: 30,000 Jobs Cut as It Pivots to Automation and Higher-Margin Deliveries

In a major strategic shift, UPS announced plans to eliminate up to 30,000 positions and close 24 facilities by 2026. The logistics giant is restructuring its network to prioritize automation and higher-margin business segments, while scaling back lower-margin volume, notably from Amazon. The move aims to reshape the company's cost structure and profitability profile amid a challenging multi-year stock performance.

Business

Atlassian's Steep Slide: Is the Collaboration Giant Now a Value Play?

After a punishing 61% decline in its share price over the past year, Atlassian finds itself at a critical juncture. With the stock trading near $118, investors are grappling with whether this represents a profound disconnect from long-term potential or a justified reassessment of growth prospects in a shifting market.